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Abstract
Introduction: The novel coronavirus pandemic has caused significant mortality throughout the world. This study was done as 
there is scarce data on mortality predictors in severe COVID-19 pneumonia patients admitted to ICU in the Indian population. 
Material and methods: A retrospective study was conducted on COVID-19 pneumonia patients admitted to tertiary care center 
during June–October 2020. The records of patients admitted to ICU were collected and data included demography, symptoms, 
comorbidites and vital parameters. Laboratory parameters included complete hemogram, random blood sugar, serum ferritin and 
LDH, renal function test, liver function test. Treatment-associated information such as the use of remdesivir, timing of initiating 
remdesivir after the symptom onset, the use of steroids, use of anticoagulants, use of HFNC, NIV, ventilator were collected. 30 
days mortality data post-discharge was collected via telephonic interview.
Results: 4,012 confirmed cases of COVID-19 were admitted to hospital, of which 560 (13.95%)   with severe pneumonia were 
included in the study. Mean age was 57.75 ± 13.96 years. The mortality rates were 54.64% among severe COVID-19 cases and 
5% among mild to moderate COVID-19 cases. The Cox multinominal regression analysis identified SpO2/FiO2 < 400, age > 50 
years, duration of symptom > 4 days, serum ferritin > 450 µg/L, respiratory rate > 23/min, the presence of comorbidities and 
non-usage of remdesivir were independently associated with increased mortality. Mortality rate at 30 days was 56.60%.
Conclusion:  Severe COVID-19 pneumonia is associated with very high mortality, especially in a resource-constrained setting. 
The use of remdesivir may have to be considered early in the course of disease to prevent excess mortality related to COVID-19. 
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Introduction
The novel coronavirus disease (COVID-19) 
has drew worldwide attention by causing the first 
pandemic by coronavirus leading to international 
public health emergency. On the 3rd November, 
2020, the World Health Organization (WHO) 
declared coronavirus outbreak as pandemic and 
public health emergency of international concern 
[1]. SARS-CoV-2 infection has caused significant 
morbidity and mortality throughout the world 
leading to immense health care burden. Current-
ly, worldwide around 55 million people have 
been infected with SARS-CoV-2,   which has re-
sulted in around 1.35 million deaths [2]. In India, 
around 9 million people have been infected and 
approximately 132 thousand people have suc-
cumbed to SARS-CoV-2  infection [3]. Very little 
attention has been paid to clinical characteristics 
and outcomes of severe COVID-19 pneumonia pa-
tients in intensive care unit (ICU), data on whom 
are scarce but are of paramount importance to 
reduce mortality in a resource-constrained set-
ting such as a government hospital. This study 
aimed to identify factors associated with mortal-
ity in patients with severe COVID-19 pneumonia 
admitted to a tertiary care COVID-19 hospital in 
South India.  




We conducted a retrospective study at a ter-
tiary care teaching hospital in South India. The 
study was approved by institutional ethics com-
mittee (SIMS/IEC/503/2020-21).
Participants and eligibility criteria
We retrospectively analyzed consecutive 
patients with severe COVID-19 pneumonia who 
had been admitted to our hospital from June to 
October 2020. Individuals aged 18 years and 
above were included in the study. Diagnosis 
of COVID-19 was defined as the patient having 
a positive result on the oropharyngeal and na-
sopharyngeal swab for SARS-CoV-2 by reverse 
transcriptase polymerase chain reaction (RT-
PCR). Our hospital used test kits provided by the 
government of Karnataka.
Classification of severity of SARS-CoV-2 in-
fection was based on the revised national guide-
lines on clinical management of SARS-CoV-2 in-
fection given by the Ministry of Health and Family 
Welfare, Government of India [4]. 
We defined severe COVID-19 pneumonia 
as an “adult with fever or suspected respiratory 
infection, plus one of the following; respiratory 
rate >3 0 breaths/min, severe respiratory distress, 
SpO2 < 90% at room air”.
Data collection
The records of patients admitted to high 
dependency unit and intensive care unit were 
collected and evaluated for predictors of mortali-
ty. Data included demographic details, symptoms 
and the duration of symptoms, comorbidities like 
diabetes, hypertension, heart disease, obesity, 
chronic kidney disease, chronic liver disease, 
malignancy, chronic respiratory diseases like 
asthma and Chronic Obstructive Pulmonary 
Disease. Clinical parameters like pulse rate, heart 
rate, blood pressure, peripheral capillary oxygen 
saturation/fraction of inspired oxygen (SpO2/FiO2) 
on admission were collected. Laboratory parame-
ters included complete hemogram (Sismex,6 part 
differential cell counter), neutrophil-lympho-
cyte ratio, random blood sugar, serum ferritin 
(Beckman), Serum Lactate Dehydrogenase (LDH) 
(ERBA EXEL 640), renal function test, liver func-
tion test, arterial blood gas, chest radiography. 
Treatment details like the use of remdesivir, the 
day of starting remdesivir after the symptom 
onset, the use of steroids, use of anticoagulants, 
use of high-flow nasal cannula, noninvasive ven-
tilation, ventilator, incidence of hospital-acquired 
infections were collected. The outcome variables 
included the length of hospital stay and mortality.
The patients were managed with support-
ive care and specific pharmacological protocols 
created by the hospital’s COVID-19 management 
guidelines committee in accordance with the gov-
ernment of Karnataka. Specific pharmacological 
treatments included systemic corticosteroids, 
low-molecular-weight heparin, oxygen and rem-
desivir. Data collected were cross-checked by 
the authors, and at the end of data entry - by an 
independent investigator. Any disagreement be-
tween two investigators was resolved by reaching 
a consensus.
A total of 4,012 patients with laboratory-con-
firmed SARS-CoV-2 were admitted during the 
study period. We excluded from the final analysis 
patients who were still receiving care in the hos-
pital at the time of preparation of this manuscript 
and those  with incomplete information.
Statistical analysis
Descriptive data are presented as frequencies 
(percentages) of discrete variables and as means 
(SDs) of continuous variables. For comparisons 
between the two groups, ANOVA test with the 
Bonferroni correction was used. c²-test was ap-
plied to evaluate categorical factors. Fischer’s 
exact test was used in case of low cell frequency. 
The Cox regression univariate and multinomial 
analysis and Kaplan-Meier analysis were used 
for survival investigation. The receiver operating 
characteristic (ROC) curves were constructed for 
age, duration of symptoms, SpO2/FiO2, serum fer-
ritin, respiratory rate and the cut-off value with 
the highest sensitivity and specificity selected as 
threshold. All statistical tests were 2-tailed, and 
factors were considered statistically significant at 
p <0.05. IBM SPSS version 22 and CDC Epi Info 
version 7 were used for analysis. 
Results
A total  of  4,012 confirmed cases of 
COVID-19 were admitted to hospital, of which 
560 (13.95%) with great severity were included 
in the study (Figure 1). Mean age of the study 
population was 57.75 ± 13.96 years. Three hun-
dred sixty-five (65.17%) were men. Hypertension 
(41.25%) followed by diabetes (41%) was the 
most common comorbidity. Dyspnea (69.46%) 
was the most frequent symptom followed by 
fever (52.5%) and cough (46.78%) (Table 1). 
Mean duration of symptoms before admission 
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was 4.11 ± 2.09 days. Remdesivir was given to 
298 (53.21%) patients. Mean duration of starting 
remdesivir after the symptom onset was 5.58 ± 
2.78 days. High-flow nasal cannula was given to 
245 (43.7%) subjects. Ninety-one (16.25%) need-
ed ventilatory support. A very high mortality, i.e. 
306 (54.64%) cases was observed at our hospital. 
Among the patients who died, nearly quarter of 
them (82 patients) died within 24–48 hours from 
admission. Secondary bacterial infection was 
noted at a late stage of the disease in 8 patients, 
and organisms isolated were Streptococcus pneu-
monia, Klebsiella pneumoniae and Staphylococ-
cus aureus.  In the Cox regression analysis, we 
observed age > 50 years, duration of symptoms 
more than 4 days, SpO2/FiO2 < 400 on admission, 
serum ferritin > 450 μg/L on admission, respira-
tory rate >23/min on admission, the presence of 
comorbidities and non-usage of remdesivir to be 
independent predictors of mortality in patients 
with severe COVID-19 pneumonia (Table 2). We 
observed an increased hazard of death by two 
days after the onset of symptoms which peaked 
on the 5th day of the symptom onset. The risk of 
death then decreased, but remained significant till 
the 8th day (Figure 2). We found steroid usage, use 
of mechanical ventilation and the day of starting 
remdesivir after the symptom onset to be inde-
pendent predictors of prolonged hospitalization 
in patients with severe COVID-19 pneumonia 
(Table 3). The presence of chronic liver disease, 
use of mechanical ventilation, day of starting 
remdesivir after the symptom onset to be inde-
pendent predictors of prolonged ICU stay in pa-
tients with severe COVID-19 pneumonia (Table 4). 
The Kaplan-Meier analysis showed statistically 
significant mortality benefit in patients who re-
ceived remdesivir and even better survival if used 
within 4 days of the symptom onset (Figure 3A 
and 3B). Only a small number of subjects (< 2%) 
succumbed post-discharge due to COVID-19-re-
lated complications with a final mortality rate at 
30 days of 56.60%.
Discussion
In the present study, we found elderly pa-
tients with male predominance more common-
ly affected by moderate to severe pneumonia 
with very high mortality rates of more than 
50%. We observed age > 50 years, duration 
of symptoms more than 4 days on admission, 
SpO2/FiO2 <400 on admission, serum ferritin > 
450 mcg/L on admission, respiratory rate >23/min 
on admission, the presence of comorbidities 
and non-usage of remdesivir to be independent 
predictors of mortality in patients with severe 
COVID-19 pneumonia. 
Elderly patients are commonly affected by 
severe pneumonia due to age-dependent de-
cline in immunity. A Korean meta-analysis of 
COVID-19 pneumonia found old age to be the risk 
factor for increased mortality [5]. Old age is an es-
tablished risk factor for various infections, includ-
ing viral infections and by far most significant pre-
dictor of mortality in COVID-19 pneumonia [6, 7]. 
Figure 1. The flowchart depicting enrolment of COVID-19 patients into the study
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Table 1.  Baseline characteristics of patients with severe COVID-19 pneumonia admitted to ICU
Variables Total (n = 560) Survived (n = 254) Death (n = 306) P-value*
Age [years], mean (SD) 57.75 (13.96) 54.39 (14.99) 60.54 (12.39) 0.004
Gender, n [%] 365 (65.17) 166 (65.35) 199 (65.03) 0.840
Symptoms, n [%]
Cough 262 (46.78) 131 (51.57) 131 (42.95) 0.083
Dyspnea 389 (69.46) 140 (55.12) 249 (81.37) 0.001
Fever 294 (52.5) 161 (63.39) 133 (43.46) 0.0001
Myalgia 61 (10.89) 41 (16.14) 20 (6.54) 0.315
Duration of symptoms before admission, 
mean (SD) [in days]
4.11 (2.09) 3.27 (1.92) 4.79 (1.98) 0.0001
Comorbidities, n [%] 343 (61.25) 115 (45.28) 228 (74.51) 0.0001
Diabetes, n [%] 230 (41) 80 (31.50) 150 (49.02) 0.016
Hypertension, n [%] 231 (41.25) 72 (28.35) 159 (51.96) 0.009
Ischemic heart disease, n [%] 48 (8.5) 11 (4.33) 37 (12.09) 0.118
Chronic kidney disease, n [%] 32 (5.7) 4 (1.57) 28 (9.17) 0.043
Chronic liver disease, n [%] 9 (1.6) 1 (0.39) 8 (2.61) 0.171
Morbid obesity, n [%] 13 (2.3) 1 (0.39) 12 (3.92) 0.092
Vitals
SpO2 at room air [on admission], mean (SD) 78.70 (18.72) 87.74 (12.17) 71.19 (19.87) 0.0001
Respiratory rate, breath/min, mean (SD) 21.37 (4.82) 19.94 (2.97) 22.5 (5.67) 0.003
Laboratory findings at the time of admission
Hemoglobin [gm%], mean (SD) 12.35 (2.14) 12.42 (2.18) 12.34 (2.08) 0.121
Total white blood cell count, mean (SD) 9.87 (6.5) 9.04 (4.59) 10.56 (7.74) 0.071
Platelet count [lakh/mm3] 2.10 (0.93) 2.24 (0.87) 2.03 (0.86) 0.081
Neutrophil Lymphocyte Ratio mean (SD) 8.02 (8.66) 5.87 (4.37) 9.80 (10.71) 0.029
Serum ferritin [µg/L], mean (SD) 539.66 (381.78) 367.2 (308.63) 632.29 (385.61) 0.0001
Serum Lactate dehydrogenase [LDH] [U/L], 
mean (SD)
845.73 (593.51) 788.1 (681.62) 866.39 (558.52) 0.160
Serum Creatinine, [mg/dl] mean (SD) 1.66 (2.08) 1.24 (1.33) 1.94 (2.51) 0.002
Random blood sugar [mg/dl] mean (SD) 215.49 (135.3) 181.32 (112.48) 239.92 (144.8) 0.002
Treatment
Remdesivir usage n [%] 298 (53.21) 165(64.96) 133(43.46) 0.019
First dose of Remdesivir after symptoms 
onset, mean (SD)
5.58 (2.78) 5.06 (3.12) 6.01 (2.37) 0.0001
Low-molecular-weight heparin, n [%] 365 (65.17) 154 (60.63) 211 (68.95) 0.161
Steroid usage n [%] 454 (81) 185 (72.83) 269 (87.91) 0.023
First dose of steroid after admission [in 
days], mean (SD)
1.22 (1.19) 1.19 (1.25) 1.24 (1.03) 0.931
High-flow nasal cannula, n [%] 245 (43.7) 41 (16.14) 204 (66.67) 0.0001
Ventilator, n [%] 91 (61.25) 3 (1.18) 88 (28.76) 0.0001
No. of days in ICU, mean (SD) 4.48 (3.23) 5.48 (3.18) 3.64 (3.04) 0.0001
No. of days of hospital stay, mean (SD) 8.71 (7.54) 12.53 (8.76) 5.52 (4.28) 0.00001
*ANOVA test with Bonferroni adjustment for multiple comparisons
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Elderly patients infected with SARS-CoV-2 tend 
to trigger hyper-activation of the immune system 
and hypercoagulation in small blood vessels lead-
ing to cytokine storm [8]. Though it is still unclear 
why the elderly are more prone to cytokine storm, 
possible mechanisms include an increase in activ-
ity and abundance of NLRP-3 (Nucleotide-binding 
oligomerization domain, Leucine rich Repeat 
and Pyrin domain containing protein 3), a com-
ponent of inflammasome in immune cells and 
alveolar macrophages in the lungs which upon 
chronic stimulation cause pulmonary fibrosis 
[9].  NLRP-3 activity is normally under  control of 
Sirtuin-2 (protein implicated in longevity) which 
reduces with age. This decline in Sirtuin-2 is 
exacerbated by SARS-CoV-2 infection and might 
Table 2. Cox univariate and multivariate analysis of factors associated with mortality in patients with severe COVID-19 
pneumonia
Variables Hazard ratio 
(95% CI)
P–value Adjusted hazard ratio 
(95% CI)
P–value
SpO2/FiO2 < 400 3.35(2.631–4.264) 0.001 2.424 (1.869–3.145) 0.0001
Age > 50 years 1.01 (1.00–1.02) 0.0001 1.589 (1.132–2.228) 0.007
Duration of symptoms > 4 days 1.23 (1.18–1.28) 0.0001 2.410 (1.659–3.502) 0.0001
Serum ferritin > 450 µg/L 1.001 (1.001–1.001) 0.0001 2.134 (1.671–2.725) 0.0001
Neutrophil to lymphocyte ratio> 7 1.02 (1.01–1.03) 0.0001 1.122 (0.880–1.429) 0.354
First dose of remdesivir after symptom onset > 4 days 1.038 (1.003–1.075) 0.038 1.234 (0.747–2.036) 0.411
Respiratory rate > 23/min 1.08 (1.06–1.10) 0.0001 1.343 (1.046–1.725) 0.021
Diabetes 1.46 (1.16–1.83) 0.001 0.835 (0.635–1.097) 0.195
Hypertension 1.12 (1.02–1.23) 0.014 0.874 (0.754–1.012) 0.072
Ischemic heart disease 1.87(1.33–2.65) 0.001 1.233 (0.857–1.774) 0.258
Chronic kidney disease 2.35 (1.59–3.48) 0.0001 1.383 (0.886–2.158) 0.153
Presence of any comorbidity 2.32 (1.79–3.0) 0.0001 1.822 (1.286–2.581) 0.001
Remdesivir usage 0.75 (0.59–0.93) 0.013 0.453 (0.342–0.599) 0.0001
Steroid usage 1.73 (1.22–2.44) 0.001 1.097 (0.749–1.608) 0.633
Creatinine > 1.5 mg/dl 1.08 (1.04–1.12) 0.001 1.161 (0.884–1.524) 0.284
Figure 2. The graph depicting hazard ratio of mortality for each day from the symptom onset and duration of hospitalization
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promote hyperactivation of NLRP3 and trigger 
cytokine storm in elderly patients [10]. Another 
possible reason for increased susceptibility to 
COVID-19 infection in the elderly could be due to 
a decrease in T-cells and subsets, which reduces 
with aging [11]. Mahase et al. found that overall 
death rate from COVID-19 was 0.66% and was 
sharply rising to 7.8% in elderly people aged over 
80 years [12]. 
Ferritin is an intracellular protein that stores 
iron and releases in a controlled fashion. Apart 
from the role of iron store, it has a potential 
capacity during inflammation following SARS-
CoV-2 infection. Ferritin is found to be secreted by 
alveolar macrophages in the lungs and also stim-
ulated by various cytokines, including IL-6 [13]. 
Active ferritin in turn stimulates the immune 
system and activates macrophages leading to an 
increase in inflammatory process [14]. Various 
single-center retrospective studies done in China 
found higher ferritin levels in patients who suc-
cumbed compared to survivors and discovered 
a decrease in ferritin levels with remission of the 
disease [15–17]. We also found elevated ferritin 
levels in non-survivors (632.29 μg/L) compared 
to survivors (367.2 μg/L).
We noted SpO2/FiO2 (SF) ratio on admis-
sion < 400 to be an independent predictor of 
mortality in severe COVID-19 pneumonia pa-
tients. SpO2/FiO2 has been used as a surrogate 
prognostic marker of PaO2/FiO2 in acute respirato-
ry distress syndrome (ARDS) patients with similar 
characteristics and the outcome in the previous 
study [18]. According to the Kigali modification, 
ARDS was defined without the need for positive 
end-expiratory pressure (PEEP), with the presence 
of bilateral opacities in the chest radiograph and 
hypoxia  defined with a cut-off of SpO2/FiO2 less 
than or equal to 315 [19]. The study done by Riv-
iello et al. using Kigali modification of the Berlin 
definition had good correlation with the diagnosis 
of ARDS [20]. SpO2/FiO2 is one of noninvasive 
parameters that might predict a poor outcome in 
patients with severe SARS-CoV-2 infection [21]. 
SpO2/FiO2 ratio could be used for correct estima-
tion of ARDS in developing countries like India, 
Table 3. Cox univariate and multivariate analysis of factors associated with prolonged hospital stay more than 5 days in 
patients with severe COVID-19 pneumonia
Variables Hazard ratio 
(95% CI)
P–value Adjusted hazard ratio 
(95% CI)
P–value
Fever 0.72 (0.581–0.90) 0.004 0.804 (0.638–1.014) 0.066
Dyspnea 1.26 (1.01–1.58) 0.036 1.04 (0.806–1.356) 0.738
Comorbidities 1.28 (1.03–1.59) 0.025 1.17 (0.930–1.17) 0.177
First dose of Remdesivir after symptom onset > 4 days 0.959 (0.929–0.989) 0.008 0.932 (0.899–0.966) 0.0001
Steroid usage 1.29 (0.98–1.71) 0.06 1.42 (1.030–1.976) 0.032
Use of ventilator 2.38 (1.58–3.59) 0.0001 2.17 (1.428–3.313) 0.0001
Table 4. Cox univariate and multivariate analysis of factors associated with prolonged ICU stay more than 4 days in patients 
with severe COVID-19 pneumonia
Variables Hazard ratio (95% CI) P–value Adjusted hazard ratio 
(95% CI)
P–value
Fever 0.670 (0.520–0.864) 0.002 0.77 (0.588–1.008) 0.062
Dyspnea 1.38 (1.07–1.80) 0.014 1.18 (0.884–1.598) 0.254
Ischemic heart disease 1.59 (0.998–2.55) 0.05 1.45 (0.869–2.44) 0.154
Chronic kidney disease 1.91 (0.981–3.73) 0.05 1.50 (0.751–3.019) 0.249
Chronic liver disease 9.49 (2.97–30.35) 0.0001 6.58 (1.94–22.27) 0.002
Comorbidities 1.44 (1.12–1.86) 0.004 1.20 (0.904–1.614) 0.202
First dose of  Remdesivir after symptom onset >4 days 0.956 (0.923–0.989) 0.015 0.940 (0.904–0.977) 0.002
Use of ventilator 3.35 (2.15–5.23) 0.0001 3.23 (2.031–5.152) 0.0001
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Figure 3. A. The Kaplan-Meier graph for survival with the use of remdesivir in patients with severe COVID-19 pneumonia; B. The Kaplan-Meier graph 
for survival with remdesivir use before and after 4 days of the symptom onset in patients with severe COVID-19 pneumonia
A
B
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where there is scarcity of critical care specialist 
and intensive care in the periphery, especially in 
the COVID-19 pandemic situation.
Several antiviral drugs have been evaluated 
for the treatment of SARS-CoV-2 infection, but 
no antiviral agents have shown any mortality 
benefit. Remdesivir, a nucleoside analog with 
broad antiviral activity among RNA viruses, 
including Ebola, has been tried for treatment of 
SARS-CoV-2 infection. It acts by interfering with 
non-structural protein 12 polymerase (nsp12) 
which is a multisubunit of RNA synthesis com-
plex that is responsible for viral RNA genome 
replication. Remdesivir has shown to decrease 
time to recovery in adults hospitalized with lower 
respiratory tract infection in an preliminary study 
of randomized control trial [22], and may prevent 
progression to more severe disease. The final re-
port showed  that remdesivir  improved mortality 
rates for those receiving supplemental oxygen 
(4% with remdesivir versus 13% with placebo 
on day 29 of treatment) [23]. A Chinese study by 
Wang et al. showed numerical reduction in time 
to improvement with remdesivir compared to pla-
cebo, however, it was not statistically significant 
[24]. A randomized controlled trial (RCT) done 
by Spinner et al. also observed  early clinical im-
provement in patients on remdesivir compared to 
standard care [25]. None of the RCTs has shown 
mortality benefit from usage of remdesivir. 
The median duration of starting remdesivir in 
our study was 5.50 days compared to studies done 
by Spinner et al., Beigel et al., Wang et al which 
was 8 days, 9 days and 11 days, respectively [22, 
24, 25].  In the above mentioned clinical trials, 
the benefit of remdesivir was larger when given 
earlier in the illness. Like other viral infections 
(eg.influenza), early use of antiviral drug is as-
sociated with improved clinical outcome [26]. 
Whether the use of remdesivir early in the course 
of disease when viral replication is the most active 
and complications have not yet occurred, would 
improve outcomes - remains to be confirmed by 
larger RCT studies.
The presence of comorbidities is an estab-
lished risk factor for mortality in patients with 
COVID-19 pneumonia in various studies done 
across the globe [27–30]. We observed comor-
bidities in nearly 61% of patients. Hypertension 
(41.25%) and diabetes (41%) were the most 
commonly  noted. Nearly 66.5% of patients with 
comorbidities succumbed to illness. A recent 
meta-analysis done in India found the preva-
lence of hypertension (22.9%) the highest among 
COVID-19 patients, and diabetes was more prev-
alent in the Indian population compared to other 
countries [30]. One of the largest Chinese studies 
(n = 72,314) found significantly increased mor-
tality in COVID-19 patients with comorbidity 
[31]. The latest report from the Center for Disease 
Control, United States discovered cardiovascular 
diseases (including hypertension, stroke, cor-
onary artery disease, cardiac failure) in 60.9% 
of patients with COVID-19 [32]. A UK study ob-
served cardiac disease, chronic obstructive pul-
monary disease, chronic kidney disease, obesity 
and liver disorders to be associated with a signif-
icant increase in mortality [33]. A recent report 
by the Ministry of Health and Family Welfare, 
India that analyzed the death of 15,962 patients 
with SARS-CoV-2 infection found the presence 
of  one or more comorbidities in 57% of patients 
[34]. Unlike other studies, our Cox multinominal 
analysis did not provide evidence for an associa-
tion between specific comorbidity and mortality.
Vital parameters play an important role in 
initial assessment and triaging of patients with 
pneumonia. Respiratory rate being one of the 
components of many severity scoring systems 
like CURB65 (Confusion, Urea, Respiratory rate, 
Blood pressure, Age > 65 years) score, APACHE 
II (Acute Physiology And Chronic Health Evalu-
ation-II) score shows its importance. We found 
increased respiratory rate (> 23/min) to be an 
independent risk factor for mortality similar to 
a large American study [35].) A Chinese study 
on 344 critically ill patients also found higher 
respiratory rate was associated with poor outcome 
indicating more attention to be paid to vital signs 
[21]. 
Due to COVID-19 pandemic, there are accel-
erated publications without long-term follow-up 
of patients with mortality data [36].) There is 
sparse information on mortality rates post-dis-
charge in severe COVID-19 pneumonia in the 
Indian population. We observed mortality rate 
of 56.60% (n = 560) in patients with severe 
COVID-19 pneumonia at 30 days which is lower 
than that from studies done in Pakistan (n-204, 
77%)  [37], the United States (n-373, 75.6%) [38] 
and China (n-344, 88.3%) [21]. However, studies 
carried out by Graselli et al. in Italy (n-1,581, 
26%) [39]) and Gupta et al. in the United States 
(n-2,215, 35.4%) [40] had lower ICU mortality 
than our study. A possible explanation for the 
disparity in mortality rates is that around 58% and 
28% of the study cohort was still in ICU without 
an outcome projecting falsely low mortality in the 
studies done by Graselli and Gupta, respectively. 
In a study conducted by Zhou et al. (n-50) who 
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followed up all patients till the outcome, the 
mortality rate was 78% [41].
Strengths and limitations
One of the important strengths of our study 
is the presence of 30 days mortality data post-dis-
charge which is lacking in many studies of pa-
tients with severe COVID-19 pneumonia. The 
evaluation of the timing of remdesivir adminis-
tration after the symptom onset on mortality rates 
is an important finding as many studies which 
did not show any benefit of remdesivir had ad-
ministered the drug late in the course of the dis-
ease. Limitations of our study include the usual 
limitations of a retrospective study, furthermore, 
information was collected from a single center.
Conclusion
We found age > 50 years, the duration of 
symptoms more than 4 days, SpO2/FiO2 < 400 on 
admission, serum ferritin > 450 μg/L on admission, 
respiratory rate > 23/min on admission, the pres-
ence of comorbidities and non-usage of remdesivir 
and late initiation of remdesivir after the symptom 
onset to be independent predictors of mortality 
in patients with severe COVID-19 pneumonia.
Clinical implication/future directions
Mortality predictors found in the study could 
be identified early and treated to possibly reduce 
mortality in severe COVID-19 pneumonia pa-
tients. Mortality benefits of remdesivir with early 
initiation in the course of the disease need to be 
relooked with large randomized controlled trials. 
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